查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930142

全球前列腺癌放射治疗市场：市场规模、占有率、成长率、行业分析、依类型、应用和地区划分的考虑因素以及未来预测（2026-2034）

Prostate Cancer Radiation Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 189 Pages | 商品交期: 请询问到货日

价格

摄护腺癌放射治疗市场的成长因素

受疾病盛行率上升、标靶放射性药物应用日益广泛以及核医学持续进步的推动，全球前列腺癌放射治疗市场预计将强劲增长。根据2025年的数据，预计2025年市场规模将达25.8亿美元，2026年将达到33.6亿美元。从长远来看，随着前列腺癌治疗中对精准放射治疗的临床依赖性不断增强，预计该市场将显着增长，到2034年将达到242.8亿美元。

此成长前景主要受全球前列腺癌负担日益加重的驱动。 2022年全球新增前列腺癌病例约1,467,854例，凸显了需要先进治疗手段的病患群体不断扩大。放射疗法利用标靶放射性同位素摧毁癌细胞，同时最大限度地减少对正常组织的损伤，由于其更高的安全性和治疗精准度，正日益取代传统放射疗法。

市场概览及关键指标

依地区划分，北美地区在前列腺癌放射治疗市场中占主导地位，预计到2025年将占62.37%的市场占有率，区域市场规模将达到16.1亿美元。这一优势得益于其先进的医疗基础设施、完善的医保报销体係以及人们对癌症早期诊断和治疗的高度重视。美国凭藉其广泛的研究活动、快速的监管审批以及创新放射性药物疗法的普及，仍然是该地区最大的市场贡献者。

欧洲占第二大市场占有率，这得益于系统性的癌症意识宣传活动，例如一年一度的 "Movember" 活动以及标靶疗法的日益普及。同时，亚太地区预计将成为成长最快的地区，这主要受人口快速老化、前列腺癌发病率上升以及澳洲、中国和日本等国家不断扩大的肿瘤学研究计画所驱动。

市场动态

市场驱动因素

人口老化是关键的成长驱动因素。摄护腺癌最常诊断于65岁以上的男性，约占2023年所有确诊病例的60.0%。预期寿命的延长、筛检计画的改进以及支持性的报销政策正在促进治疗普及和市场持续成长。

市场限制因子

儘管前景光明，但放射治疗的高昂费用仍然是一个挑战。例如，单次镥-177疗法的费用可能超过5万美元，这限制了其在对成本敏感地区的普及。此外，发展中国家缺乏专业的核子医学基础设施和复杂的监管要求也持续阻碍市场渗透。

市场机会

放射性同位素供应的策略联盟是一个重要的机会领域。製药公司与同位素生产商之间的合作正在提高供应链的稳定性，并加速下一代放射性药物的临床开发。这些合作有望支持市场的长期规模化和创新。

市场趋势

影响市场的最重要趋势之一是诊疗一体化（theranostics）的扩展，它将诊断影像和标靶治疗相结合。这种个人化治疗方法使临床医生能够在进行放射性配体治疗之前，利用分子影像识别合适的患者，从而改善治疗效果并减少副作用。全球企业对诊疗一体化产品线的持续投入，印证了其在前列腺癌治疗领域日益增长的重要性。

市场区隔洞察

依放射性同位素

镥-177凭藉其获得多项监管批准和显着的临床疗效，占市场主导地位。 Pluvicto等产品进一步巩固了该细分市场的地位。镭-223的应用持续稳定成长，其他新兴放射性同位素也透过持续的研究合作而获得关注。

依类型

转移性去势抵抗性前列腺癌（mCRPC）细分市场占最大的市场占有率，这主要归因于该疾病的严重性以及对先进标靶疗法的强劲需求。随着各公司日益关注早期干预，非转移性前列腺癌细分市场也不断扩张。

依最终使用者划分

截至2025年，拥有先进放射治疗基础设施和经验丰富的肿瘤科医生的医院占了最大的市场占有率。随着患者对强化、个人化癌症治疗的需求日益增长，专科诊所的发展势头强劲。

本报告详细分析了2025年、2026年和2034年的市场规模和价值，并深入探讨了市场动态、市场细分、区域展望、竞争格局和关键发展趋势。报告全面展望了市场的未来发展轨迹，尤其关注监管审批、产品发布、合作趋势以及精准放射治疗在前列腺癌治疗中不断演变的作用。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区前列腺癌盛行率（2025 年）
  • 主要公司产品线分析
  • 替代疗法概述
  • 主要公司新产品发布
  • 关键产业趋势：併购、业务合作等
  • 新冠疫情的影响市场

第五章 全球前列腺癌放射治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依放射性同位素划分
    • 镭-223
    • 镥-177
    • 其他
  • 市场分析、洞察与预测：依类型划分
    • 转移性去势抵抗性摄护腺癌
    • 非转移性去势抵抗性摄护腺癌
  • 市场分析、洞察与预测：依最终用户划分
    • 医院
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美美洲
    • 欧洲
    • 亚太地区
    • 世界其他地区 (ROW)

第六章 北美摄护腺癌放射治疗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲前列腺癌放射治疗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区前列腺癌放射治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：世界其他地区（ROW）前列腺癌放射治疗市场分析：洞察与预测（2021-2034）

第10章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
  • Novartis AG
  • Bayer AG
  • Telix Pharmaceuticals Limited
  • Ariceum Therapeutics
  • Radiopharm Theranostics Limited
  • Lantheus Holdings, Inc.
  • Clarity Pharmaceuticals
Product Code: FBI112713

Growth Factors of prostate cancer radiation therapeutics Market

The global prostate cancer radiation therapeutics market is positioned for strong expansion, supported by rising disease prevalence, growing adoption of targeted radiopharmaceuticals, and continuous advancements in nuclear medicine. According to the 2025 report year data, the market was valued at USD 2.58 billion in 2025 and is projected to reach USD 3.36 billion in 2026. Over the long term, the market is forecast to grow substantially and attain USD 24.28 billion by 2034, reflecting the increasing clinical reliance on precision radiation therapies for prostate cancer management.

The growth outlook is primarily driven by the escalating global burden of prostate cancer. In 2022, approximately 1,467,854 new prostate cancer cases were recorded worldwide, highlighting the expanding patient pool requiring advanced therapeutic interventions. Radiation therapeutics, which utilize targeted radioisotopes to destroy cancer cells while minimizing damage to healthy tissues, are increasingly preferred over conventional radiation techniques due to their improved safety and treatment precision.

Market Overview and Key Metrics

From a regional standpoint, North America dominated the prostate cancer radiation therapeutics market in 2025 with a market share of 62.37%, translating to a regional market size of USD 1.61 billion. This dominance is supported by advanced healthcare infrastructure, strong reimbursement frameworks, and high awareness levels regarding early cancer diagnosis and treatment. The United States remains the largest contributor within the region due to extensive research activities, rapid regulatory approvals, and widespread access to innovative radiopharmaceutical therapies.

Europe holds the second-largest share of the market, supported by structured cancer awareness initiatives such as annual Movember campaigns and rising adoption of targeted therapies. Meanwhile, Asia Pacific is projected to be the fastest-growing region, driven by a rapidly aging population, increasing prostate cancer incidence, and expanding oncology research programs across countries such as Australia, China, and Japan.

Market Dynamics

Market Drivers

A key growth driver is the expanding geriatric population. Prostate cancer is most commonly diagnosed in men aged 65 years and above, accounting for approximately 60.0% of total diagnosed cases in 2023. Increased life expectancy, improved screening programs, and supportive reimbursement policies are collectively contributing to higher treatment uptake and sustained market growth.

Market Restraints

Despite its promising outlook, the market faces challenges due to the high cost of radiation therapeutics. For example, a single dose of Lutetium-177-based therapy can cost over USD 50,000, which limits accessibility in cost-sensitive regions. Additionally, the lack of specialized nuclear medicine infrastructure and complex regulatory requirements in developing economies continue to restrict market penetration.

Market Opportunities

Strategic collaborations for radioisotope supply represent a major opportunity area. Partnerships between pharmaceutical companies and isotope manufacturers are improving supply chain stability and accelerating clinical development of next-generation radiopharmaceuticals. Such collaborations are expected to support long-term market scalability and innovation.

Market Trends

One of the most significant trends shaping the market is the expansion of theranostics, which integrates diagnostic imaging with targeted therapy. This personalized treatment approach allows clinicians to identify suitable patients using molecular imaging before administering radioligand therapies, improving treatment outcomes and reducing adverse effects. Increasing investments in theranostic pipelines by global players underscore its growing importance in prostate cancer care.

Segmentation Insights

By Radioisotope

The Lutetium-177 segment dominated the market due to multiple regulatory approvals and strong clinical efficacy. Products such as Pluvicto have strengthened this segment's position. Radium-223 continues to show steady adoption, while other emerging radioisotopes are gaining traction through ongoing research collaborations.

By Type

The metastatic castration-resistant prostate cancer (mCRPC) segment accounts for the largest market share, driven by higher disease severity and greater demand for advanced targeted treatments. The non-metastatic segment is also expanding as companies increasingly focus on early-stage intervention.

By End User

Hospitals held the leading share in 2025 due to their advanced radiotherapy infrastructure and skilled oncology professionals. Specialty clinics are gaining momentum as patients seek focused and personalized cancer care.

Competitive Landscape

The global prostate cancer radiation therapeutics market is highly consolidated. Leading players such as Novartis AG and Bayer AG account for a significant share, supported by approved products and strong R&D pipelines. Other notable participants include Telix Pharmaceuticals, Lantheus Holdings, Clarity Pharmaceuticals, Radiopharm Theranostics, and Ariceum Therapeutics, all of which are actively investing in next-generation radiopharmaceutical development.

Report Scope

The 2025 report provides a detailed analysis of market size and value for 2025, 2026, and 2034, along with in-depth insights into market dynamics, segmentation, regional outlook, competitive landscape, and key industry developments. The coverage emphasizes regulatory approvals, product launches, collaborations, and the evolving role of precision radiation therapies in prostate cancer treatment, offering a comprehensive view of the market's future trajectory.

Conclusion

The prostate cancer radiation therapeutics market is entering a phase of accelerated transformation, supported by strong clinical demand, rapid technological advancement, and expanding acceptance of targeted radiopharmaceuticals. With the market valued at USD 2.58 billion in 2025, projected to reach USD 3.36 billion in 2026, and forecast to surge to USD 24.28 billion by 2034, the outlook clearly reflects the growing clinical reliance on precision radiation therapies. High disease prevalence, particularly among men aged 65 years and above, and the increasing shift toward personalized medicine are reinforcing long-term demand. North America's dominance, holding 62.37% market share in 2025, highlights the importance of advanced healthcare infrastructure and favorable reimbursement environments, while Asia Pacific's rapid expansion signals emerging opportunities. Despite challenges related to high treatment costs and regulatory complexity, ongoing collaborations, theranostics adoption, and robust R&D pipelines from leading companies are expected to sustain strong momentum. Overall, the market is well-positioned for sustained expansion through 2034, driven by innovation, precision oncology trends, and rising global prostate cancer burden.

Segmentation By Radioisotope, Type, End-User, and Region

By Radioisotope * Radium-223

  • Lutetium-177
  • Others

By Type * Metastatic Castration-Resistant Prostate Cancer

  • Non-Metastatic Castration-Resistant Prostate Cancer

By End-User * Hospitals

  • Specialty Clinics
  • Others

By Region * North America (By Radioisotopes, Type, End-User, and Country)

    • U.S.
    • Canada
  • Europe (By Radioisotopes, Type, End-User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Radioisotopes, Type, End-User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Radioisotopes, Type, and End-User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Market

5. Global Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 5.1.1. Radium-223
    • 5.1.2. Lutetium-177
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals
    • 5.3.2. Specialty Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 6.1.1. Radium-223
    • 6.1.2. Lutetium-177
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals
    • 6.3.2. Specialty Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 7.1.1. Radium-223
    • 7.1.2. Lutetium-177
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 8.1.1. Radium-223
    • 8.1.2. Lutetium-177
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals
    • 8.3.2. Specialty Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 9.1.1. Radium-223
    • 9.1.2. Lutetium-177
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.2.1. Novartis AG
    • 10.2.2. Bayer AG
    • 10.2.3. Telix Pharmaceuticals Limited
    • 10.2.4. Ariceum Therapeutics
    • 10.2.5. Radiopharm Theranostics Limited
    • 10.2.6. Lantheus Holdings, Inc.
    • 10.2.7. Clarity Pharmaceuticals

List of Tables

  • Table 1: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 2: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 3: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 4: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 6: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 8: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 10: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 11: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 12: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 14: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 15: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 16: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 18: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 19: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Radiation Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025 & 2034
  • Figure 3: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025 & 2034
  • Figure 5: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 6: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 7: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 9: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 10: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 11: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 12: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country, 2025
  • Figure 13: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 14: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 15: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 16: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 17: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 18: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 19: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 20: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 21: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 22: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 23: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 24: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 25: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 26: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 27: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 30: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 31: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 32: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 33: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 34: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 35: Global Prostate Cancer Radiation Therapeutics Market Share (%), By Company, 2025